Abstract
Purpose To report on the anatomic and visual acuity response after intravitreal bevacizumab injection in patients with macular edema due to non-ischemic central retinal vein occlusion (CRVO). Methods In a retrospective study, 21 consecutive patients (21 eyes) with non-ischemic CRVO underwent, on average, 3.7 intravitreal bevacizumab injections (1.25 mg). Ophthalmic examination included best corrected visual acuity (BCVA) and central retinal thickness (CRT) at baseline and follow-up visits. Fluorescein angiography was performed at baseline and at follow-up visits if needed. Primary outcomes were change of BCVA and CRT. Results The follow-up period for all of the included patients was 12 months. The mean BCVA was unchanged at the 12-month examination (baseline: 20/160; 12 months: 20/160) (P = 0.771). The mean CRT decreased from 780 μm (standard deviation [SD] ± 324 μm) at the baseline to a mean of 462 μm (SD ± 248 μm) at 12 months (P < 0.05). Conclusion Intravitreal bevacizumab resulted in a significant decrease in CRT without significant improvement of visual acuity in patients with non-ischemic CRVO after a follow-up of 12 months.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
The Central Vein Occlusion Study Group M Report (1995) Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. Ophthalmology 102:1425–1433
Mohamed Q, McIntosh RL, Saw SM et al (2007) Interventions for central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 114:507–519. doi:10.1016/j.ophtha.2006.11.011, 524
Costa RA, Jorge R, Calucci D et al (2007) Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 27:141–149. doi:10.1097/IAE.0b013e31802eff83
Hsu J, Kaiser RS, Sivalingam A et al (2007) Intravitreal bevacizumab (avastin) in central retinal vein occlusion. Retina 27:1013–1019
Iturralde D, Spaide RF, Meyerle CB et al (2006) Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26:279–284. doi:10.1097/00006982-200603000-00005
Pai SA, Shetty R, Vijayan PB et al (2007) Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 143:601–606. doi:10.1016/j.ajo.2006.12.037
Priglinger SG, Wolf AH, Kreutzer TC et al (2007) Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina 27:1004–1012
Schaal KB, Höh AE, Scheuerle A et al (2007) Bevacizumab zur Therapie des Makulaödems infolge venöser retinaler Gefäßverschlüsse. Ophthalmologe 104:285–289. doi:10.1007/s00347-007-1509-x
Spandau UH, Ihloff AK, Jonas JB (2006) Intravitreal bevacizumab treatment of macular oedema due to central retinal vein occlusion. Acta Ophthalmol Scand 84:555–556. doi:10.1111/j.1600-0420.2006.00740.x
Stahl A, Agostini H, Hansen LL et al (2007) Bevacizumab in retinal vein occlusion—results of a prospective case series. Graefes Arch Clin Exp Ophthalmol 245:1429–1436. doi:10.1007/s00417-007-0569-6
Matsumoto Y, Freund KB, Peiretti E et al (2007) Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina 27:426–431. doi:10.1097/IAE.0b013e31804a7af2
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
The authors have no financial interest related to the manuscript.
Rights and permissions
About this article
Cite this article
Beutel, J., Ziemssen, F., Lüke, M. et al. Intravitreal bevacizumab treatment of macular edema in central retinal vein occlusion: one-year results. Int Ophthalmol 30, 15–22 (2010). https://doi.org/10.1007/s10792-008-9282-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10792-008-9282-7